ETI, 5,8,11-eicosatriynoic acid, demonstrates the ability to inhibit 5-LO (5-lipoxygenase) activity and halt biosynthesis of leukotriene C4 by mastocytoma cells. Studies suggest that ETI also reduces oxidative metabolism of arachidonic acid (sc-200770). ETI also displays anti-proliferative properties which result from 5-LO selective inhibition and cause a decrease in platelet-induced growth of fibroblast cells. ETI is an inhibitor of 12-LO, 15-LO and GST.
1. Orning, L. and Hammarström, S. 1980. J. Biol. Chem. 255: 8023-8026. PMID: 6106018
2. Salari, H., et al. 1984. Prostaglandins Leukot Med. 13: 53-60. PMID: 6424136
3. Berg, C., et al. 2006. Thromb. Haemost. 96: 652-659. PMID: 17080223
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.